Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLCN2 | P51788 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | XDH | P47989 | 3/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.49 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.48 |
| ▸ | OXTR | P30559 | 1/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4225654 | 0.88 | CLCN2 (0.50) | CLCN2XDHSLC22A12AVPR2OXTR | |
| SCHEMBL4225312 | 0.87 | XDH (0.51) | CLCN2XDHSLC22A12AVPR2OXTR | |
| SCHEMBL4222396 | 0.86 | XDH (0.52) | CLCN2XDHSLC22A12AKR1C3AKR1C2 | |
| SCHEMBL4215551 | 0.85 | GRIK1 (0.54) | CLCN2XDHSLC22A12AVPR2OXTR | |
| SCHEMBL4226484 | 0.85 | XDH (0.54) | XDHSLC22A12AKR1C3AKR1C2GRIK1 | |
| SCHEMBL4215552 | 0.84 | AKR1C3 (0.53) | CLCN2NPC1RAB9ASMN1; SMN2AKR1C3 | |
| SCHEMBL4216624 | 0.84 | GRIK1 (0.58) | XDHSLC22A12AKR1C3AKR1C2GRIK1 | |
| SCHEMBL4223054 | 0.84 | AKR1C3 (0.59) | CLCN2NPC1SMN1; SMN2XDHSLC22A12 | |
| SCHEMBL4219566 | 0.84 | CLCN2 (0.48) | CLCN2XDHSLC22A12AVPR2OXTR | |
| SCHEMBL4221446 | 0.84 | XDH (0.49) | CLCN2XDHSLC22A12AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8327467-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1860098-B1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| EP-2079699-A1 | QUINOLINE DERIVATIVES | Envivo Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| WO-2008014602-A1 | QUINOLINE DERIVATIVES | ENVIVO PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1860098-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP11, MMP3 | CLCN2 1704/4885NPC1 4833/4885RAB9A 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.